Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire May Split Up – But Punting On Bigger Decisions For Now

Executive Summary

The specialty pharma is dividing its operations into rare disease and neuroscience units, but whether that will mean a spinout for the latter won't be revealed for months.

Advertisement

Related Content

Mum On Takeda, Shire Outlines Two-Division Performance
Pharma Q1 Results Preview: Shire, AbbVie, Bristol, Sanofi, Allergan
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
Takeda's Interest Likely To Flush Out Further Shire Suitors
Immunology Leads Shire's 2017 Sales Growth With Addition Of HAE Portfolio
Deal Watch: Sanofi Finds Ideal 'Partner' For Leukine
Shire CEO: Mydayis To Be Big ADHD Drug, But No Ex-US Launch Planned (Yet)
Stronger Together: Pfizer Decides Against A Split
Shire/Baxalta Merger's Benefits Doubted By Wall Street

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100164

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel